Page last updated: 2024-08-21

quinazolines and Synovioma

quinazolines has been researched along with Synovioma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kwan, W; Liu, S; Lubieniecka, JM; Nielsen, TO; Terry, J	1
Blay, JY; Bui, BN; Hogendoorn, P; Le Cesne, A; Marreaud, S; Ray-Coquard, I; Schoffski, P; van Glabbeke, M; Verweij, J; Whelan, JS	1

Trials

1 trial(s) available for quinazolines and Synovioma

Article	Year
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. The oncologist, 2008, Volume: 13, Issue:4 Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sarcoma, Synovial; Treatment Failure; Treatment Outcome	2008

Article

Year

A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.

The oncologist, 2008, Volume: 13, Issue:4

Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sarcoma, Synovial; Treatment Failure; Treatment Outcome

2008

Other Studies

1 other study(ies) available for quinazolines and Synovioma

Article	Year
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab	2005

Article

Year

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab

2005